Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice

Basit Öğe Kaydı
dc.contributor.authorGurdogan, Muhammet
dc.contributor.authorDemir, Melik
dc.contributor.authorYalta, Kenan
dc.contributor.authorGurlertop, Yekta
dc.date.accessioned2024-06-12T10:55:45Z
dc.date.available2024-06-12T10:55:45Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCancer therapy-related pulmonary hypertension is a rare yet potentially fatal cardiotoxicity. However, it is a reversible cause of pulmonary hypertension if detected in its early stages. Cancer therapy-related pulmonary hypertension has been encountered in patients using tyrosine kinase inhibitors, particularly dasatinib. However, it is also well known that many agents used in cancer treatment such as alkylating agents, proteasome inhibitors, thoracic radiation exposure, and immune checkpoint inhibitors are particularly associated with pulmonary hypertension evolution. In case that history, symptoms, and clinical findings suggest a potential cancer therapy-related pulmonary hypertension, echocardiography is considered as the initial tool to detect pulmonary hypertension. If the possibility of pulmonary hypertension is high based on echocardiographic data, cancer treatment, as the initial step, should be discontinued due to its potential risks and other causes for pulmonary hypertension should be investigated thoroughly. Right heart catheterization should be the next step to establish the final diagnosis, and medical management, where appropriate, should be started without delay in these patients according to their pulmonary hypertension subgroup. There exists limited information regarding the diagnostic and management strategies of cancer therapy-related pulmonary hypertension in the current guidelines. In this review article, we aim to present current literature data on the mechanisms and management of cancer therapy-related pulmonary hypertension along with its follow-up algorithm in the setting of cardio-oncology practice.en_US
dc.identifier.doi10.14744/AnatolJCardiol.2023.3013
dc.identifier.endpage307en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue6en_US
dc.identifier.pmid37257013en_US
dc.identifier.scopus2-s2.0-85160694969en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage299en_US
dc.identifier.trdizinid1179777en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2023.3013
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1179777
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19541
dc.identifier.volume27en_US
dc.identifier.wosWOS:001070506600004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofAnatolian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCardio-Oncologyen_US
dc.subjectCardiotoxicityen_US
dc.subjectChemotherapyen_US
dc.subjectRadiotherapyen_US
dc.subjectPulmonary Hypertensionen_US
dc.subjectArterial-Hypertensionen_US
dc.subjectFibrosisen_US
dc.titleCancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practiceen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu